<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380298</url>
  </required_header>
  <id_info>
    <org_study_id>KY-2018-034-02-7</org_study_id>
    <nct_id>NCT04380298</nct_id>
  </id_info>
  <brief_title>Effects of Pre-emptive Scalp Infiltration With Low-dose Ketorolac and Ropivacaine for Postoperative Pain</brief_title>
  <acronym>PAINLESS</acronym>
  <official_title>Effects of Pre-emptive Scalp Infiltration With Low-dose Ketorolac and Ropivacaine for Postoperative Pain Relief After Elective Supratentorial Craniotomy (PAINLESS): a Randomized Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PAINLESS study is a single-center, prospective, randomized, open-label, blinded-endpoint
      (PROBE) controlled clinical pilot study to compare the efficacy and safety of pre-emptive
      scalp infiltration with ropivacaine plus ketorolac and ropivacaine alone for postoperative
      pain relief in adults undergoing elective supratentorial craniotomies.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative doses of patient-controlled analgesia (PCA) sufentanil consumption</measure>
    <time_frame>0 to 48 hours postoperatively</time_frame>
    <description>cumulative doses of patient-controlled analgesia (PCA) butorphanol consumption from 0 to 48 h postoperatively The primary outcome measure will be cumulative doses of PCA butorphanol consumption from 0 to 48 h postoperatively</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to first request for PCA sufentanil</measure>
    <time_frame>0 to 48 hours postoperatively</time_frame>
    <description>The time to first request for patient-controlled analgesia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency of pressing PCA pump</measure>
    <time_frame>Within 48hours postoperatively</time_frame>
    <description>frequency of pressing PCA pump</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>numeral rating scale (NRS) Score</measure>
    <time_frame>at 2 hours, 4 hours, 8 hours, 24 hours, 48 hours postoperatively</time_frame>
    <description>0 for&quot;no pain&quot; and 10 for &quot;pain as severe as you can imagine&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain control satisfaction score (PCSS) postoperatively</measure>
    <time_frame>at 24 hours and 48 hours post-operation</time_frame>
    <description>0 for unsatisfactory and 10 for very satisfactory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ramsay sedation score (RSS)</measure>
    <time_frame>at 2 hours, 4 hours, 8 hours, 24 hours and 48 hours postoperatively</time_frame>
    <description>1: Anxious, agitated, restless; Ramsey 2: Cooperative, oriented, tranquil; Ramsey 3: Responsive to commands only If Asleep; Ramsey 4: Brisk response to light glabellar tap or loud auditory stimulus; Ramsey 5: Sluggish response to lightglabellar tap or loud auditory stimulus; Ramsey 6: No response to light glabellar tap or loud auditory stimulus.Asleep; Ramsey 4: Brisk response to light glabellar tap or loud auditory stimulus; Ramsey 5: Sluggish response to lightglabellar tap or loud auditory stimulus; Ramsey 6: No response to light glabellar tap or loud auditory stimulus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse oxygen saturation(SpO2)</measure>
    <time_frame>1 minutes before anesthesia induction, 1 minutes after anesthesia induction, 1 minutes after scalp infiltration, at the beginning of skull drilling, mater cutting and skin closure and at 2hours, 4 hours, 8 hours , 24 hours and 48 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean arterial blood pressure(MAP)</measure>
    <time_frame>1 minutes before anesthesia induction, 1 minutes after anesthesia induction, 1 minutes after scalp infiltration, at the beginning of skull drilling, mater cutting and skin closure and at 2hours, 4 hours, 8 hours , 24 hours and 48 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate(HR)</measure>
    <time_frame>1 minutes before anesthesia induction, 1 minutes after anesthesia induction, 1 minutes after scalp infiltration, at the beginning of skull drilling, mater cutting and skin closure and at 2hours, 4 hours, 8 hours , 24 hours and 48 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory rate(RR)</measure>
    <time_frame>1 minutes before anesthesia induction, 1 minutes after anesthesia induction, 1 minutes after scalp infiltration, at the beginning of skull drilling, mater cutting and skin closure and at 2hours, 4 hours, 8 hours , 24 hours and 48 hours postope</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Length of hospital stay, an arverage of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative nausea and vomiting(PONV)</measure>
    <time_frame>within 48 hours postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The presence of respiratory depression</measure>
    <time_frame>within 48 hours postoperatively</time_frame>
    <description>respiratory rate &lt;10 breaths per minute or SpO2 was&lt;90 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of haematoma, wound infection or gastric ulcers</measure>
    <time_frame>during hospitalization, within 2 weeks postoperatively</time_frame>
    <description>side effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pain</condition>
  <condition>Supratentorial Brain Tumor</condition>
  <arm_group>
    <arm_group_label>The ketorolac group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to the ketorolac group will receive pre-emptive scalp infiltration with 30ml of local infiltration solution containing 60 mg ropivacaine, 6 mg ketorolac and 0.1mg epinephrine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the control group, preoperative peri-incisional scalpinfiltration will be performed using 30ml of 60 mgropivacaine and 0.1mg epinephrine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>30ml of local infiltration solution containing 60mg ropivacaine</description>
    <arm_group_label>The ketorolac group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>30ml of local infiltration solution containing 6mg ketorolac</description>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_label>The ketorolac group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epinephrine</intervention_name>
    <description>30ml of local infiltration solution containing 0.1mg epinephrine</description>
    <arm_group_label>The control group</arm_group_label>
    <arm_group_label>The ketorolac group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for elective supratentorial tumour resection;

          -  Planned general anaesthesia;

          -  American Society of Anesthesiologists (ASA) physical status I - II;

          -  Age ranging from 18 to 65 years old;

          -  Participates required to fix their head in a head clamp intraoperatively;

          -  Participates with an anticipated awake within 2 hours after surgery.

        Exclusion Criteria:

          -  Allergy/intolerance to study drugs including anesthetic drugs, ketorolac and
             epinephrine;

          -  Expected delayed extubation or no plan to extubate;

          -  History of neurosurgeries;

          -  Long-term use of analgesics and sedatives (more than 2 weeks)

          -  Receiving any painkiller within 24 h before the operation;

          -  Extreme body mass index (BMI) (less than 15 or more than 35);

          -  Patients with impaired cardiopulmonary;

          -  Patients with impaired renal function;

          -  Patients with impaired hepatic function;

          -  History of chronic headache;

          -  Patients with cognitive deficit;

          -  Patients with intellectual disability;

          -  Patients with uncontrolled epilepsy;

          -  Patients with psychiatric disorders;

          -  Difficulties in using PCA device

          -  Difficulties in understanding the use of numeral rating scale (NRS) ;

          -  Patients with suspected intracranial hypertension;

          -  Pregnant or at breastfeeding;

          -  Infection at the incisional site;

          -  History of radiation therapy and chemotherapy preoperatively

          -  With great likelihood of postoperative radiation therapy and chemotherapy based on
             preoperative imaging.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fang Luo, M.D</last_name>
    <phone>+8613611326978</phone>
    <email>13611326978@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yitong Jia, M.D</last_name>
    <phone>+8613811109032</phone>
    <email>13811109032@163.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Song J, Li L, Yu P, Gao T, Liu K. Preemptive scalp infiltration with 0.5% ropivacaine and 1% lidocaine reduces postoperative pain after craniotomy. Acta Neurochir (Wien). 2015 Jun;157(6):993-8. doi: 10.1007/s00701-015-2394-8. Epub 2015 Apr 7.</citation>
    <PMID>25845547</PMID>
  </reference>
  <reference>
    <citation>Kerr DR, Kohan L. Local infiltration analgesia: a technique for the control of acute postoperative pain following knee and hip surgery: a case study of 325 patients. Acta Orthop. 2008 Apr;79(2):174-83. doi: 10.1080/17453670710014950.</citation>
    <PMID>18484242</PMID>
  </reference>
  <reference>
    <citation>Niemeläinen M, Kalliovalkama J, Aho AJ, Moilanen T, Eskelinen A. Single periarticular local infiltration analgesia reduces opiate consumption until 48 hours after total knee arthroplasty. A randomized placebo-controlled trial involving 56 patients. Acta Orthop. 2014 Dec;85(6):614-9. doi: 10.3109/17453674.2014.961399. Epub 2014 Sep 19.</citation>
    <PMID>25238439</PMID>
  </reference>
  <reference>
    <citation>Andersen KV, Nikolajsen L, Haraldsted V, Odgaard A, Søballe K. Local infiltration analgesia for total knee arthroplasty: should ketorolac be added? Br J Anaesth. 2013 Aug;111(2):242-8. doi: 10.1093/bja/aet030. Epub 2013 Mar 20.</citation>
    <PMID>23514638</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Fang Luo</investigator_full_name>
    <investigator_title>Director of Department of Pain Management</investigator_title>
  </responsible_party>
  <keyword>Pre-emptive Scalp Infiltration</keyword>
  <keyword>Ketorolac</keyword>
  <keyword>Postoperative Pain</keyword>
  <keyword>Supratentorial Craniotomy</keyword>
  <keyword>A pilot Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

